Kisspeptin-10 Dosage Guide: Protocols, Calculator & Safety

Context: KP-10 is most commonly used off-label for two purposes: (1) supporting HPG axis recovery after exogenous androgen or TRT suppression, and (2) enhancing sexual desire or exploring central kisspeptin effects. Protocols differ accordingly.

Reconstitution: A 5 mg KP-10 vial reconstituted with 2 mL of bacteriostatic water yields a 2.5 mg/mL solution. On a U-100 insulin syringe: 1 unit (0.01 mL) = 25 mcg, 4 units = 100 mcg, 10 units = 250 mcg, 20 units = 500 mcg.

Protocol A: Axis Recovery Support After Cycle (most common off-label use)

Intended for men in the post-cycle recovery phase after anabolic androgens or during TRT break. Usually combined with hCG and/or a SERM (clomiphene/enclomiphene) rather than used alone.

• Weeks 1-4 of recovery: KP-10 100 mcg subcutaneous twice daily (morning and evening). Because KP-10's plasma half-life is only ~4 minutes, twice-daily dosing provides pulsatile stimulation but not continuous axis drive — matching the intermittent physiological pattern of kisspeptin neuron firing.
• Weeks 5-8: KP-10 100 mcg subcutaneous once daily (morning), alongside taper of other recovery agents.
• Assess axis recovery with labs: LH, FSH, total testosterone, free testosterone, estradiol at 4 weeks and 8 weeks into recovery. Restoration of LH pulsatility and testosterone into the normal range indicates axis function is returning.

Protocol B: Sexual Desire / HSDD Exploration

For users interested in kisspeptin's libido effects (less well-established than axis recovery uses but the emerging research direction):

• KP-10 100-200 mcg subcutaneous 30-90 minutes before desired effect window
• On-demand dosing rather than chronic scheduled dosing
• May be repeated daily during active interest phase without significant tolerance development
• Not a long-term daily regimen for HSDD — the data supports acute rather than chronic use

Protocol C: Ovulation Induction (medical context only)

Kisspeptin ovulation induction should be performed only under reproductive endocrinology supervision. Typical research protocols use KP-54 (not KP-10) at 9.6 nmol/kg IV as a single trigger dose replacing hCG. Self-administered KP-10 for ovulation induction outside clinical supervision is strongly discouraged — timing, dosing, and oocyte maturation assessment require ultrasound and laboratory monitoring.

What to Expect:

• Subtle effects rather than dramatic acute sensations for axis-recovery use. Day-to-day, most users feel little acute change from KP-10 itself; effects are measured by lab trends and gradual return of libido, energy, and morning erections over weeks.
• More noticeable acute effects for sexual-desire use — increased libido, genital sensitivity, and emotional engagement within 1-2 hours of dosing for many users.

When to Stop:

• No adverse events in short-term use so far make this a difficult question, but reasonable stopping points include: axis labs showing full recovery (for protocol A), no subjective response after 2-4 weeks (likely inadequate dosing or indication mismatch), or any unexplained symptoms.
• Cycle breaks: even though kisspeptin has not shown tachyphylaxis in short trials, a 2-4 week break after any 8-12 week block of daily use is a reasonable conservative practice.

Important Note on Comparison to Gonadorelin: Users choosing between KP-10 and Gonadorelin for axis support should understand the difference: gonadorelin is GnRH and stimulates the pituitary directly; KP-10 stimulates hypothalamic GnRH neurons and requires an intact hypothalamus-to-pituitary chain. If the axis is suppressed at the hypothalamic level (most common in exogenous androgen use), KP-10 is more physiologically complete; if the pituitary is impaired, gonadorelin is more direct.

For users who have completed at least one KP-10 cycle and want to optimize dosing.

Pulsatile Dosing (more physiological): Endogenous GnRH pulses occur roughly every 60-120 minutes in normal physiology. Attempting to mimic this with KP-10:

• 50-100 mcg subcutaneous every 90-120 minutes during waking hours
• Practically difficult (8-10 injections per day) but produces the most physiological axis drive
• Usually reserved for short intensive "kickstart" periods rather than sustained months-long regimens
• Subcutaneous infusion pumps (insulin-style micro-pumps) are used in some clinical research to deliver pulsatile kisspeptin automatically — these are not typically accessible to community users

Standard Twice-Daily Dosing at Higher Doses:

• 200-500 mcg subcutaneous twice daily (up from the beginner 100 mcg BID)
• Produces stronger axis drive at the cost of higher plasma peaks and higher cumulative dose
• Consider this if the beginner protocol produces only partial recovery

Dose-Response Tuning: The kisspeptin dose-response for LH/FSH release plateaus around 500-1000 mcg in most studies — doses higher than this produce disproportionately increased side-effect risk without additional axis drive. Stay in the 100-500 mcg per dose range for most off-label use.

Protocol Combinations:

• KP-10 + HCG + Enclomiphene during post-cycle recovery represents a common "triple stack" targeting hypothalamus (KP-10), pituitary (enclomiphene via estrogen feedback blockade), and gonad (HCG). Run 8-12 weeks then assess labs.
• Cyclical KP-10 — 4 weeks on, 2 weeks off, 4 weeks on — to avoid theoretical desensitization concerns. Not supported by clinical evidence but a reasonable conservative approach.

Desire/HSDD Refinement:

• Timing 60-90 minutes before anticipated sexual activity optimizes the window when central kisspeptin effects peak
• Combining on-demand KP-10 with an oral PDE5 inhibitor (for men) or a topical approach (for women) targets central and peripheral sexual function mechanisms simultaneously
• Kisspeptin effects appear to build somewhat over repeated exposures — the first few doses may produce little subjective effect and benefit accrues over 2-4 weeks of regular use

Monitoring:

• Axis labs every 4-8 weeks during active use (LH, FSH, total T, free T, estradiol, SHBG, prolactin)
• Symptom tracking — morning erections, energy, libido, mood — as subjective complement to labs
• CBC and basic metabolic panel at baseline; no specific kisspeptin-related lab abnormalities expected but useful to establish baseline

Still Recommended:

• Adequate sleep, caloric intake, and micronutrients
• Avoid alcohol excess during recovery
• Contraception if any risk of pregnancy (kisspeptin can induce ovulation)

For experienced users with specific clinical contexts and/or collaboration with an endocrinology-literate physician.

Scenario 1: Long-Standing Suppression After Multi-Year Exogenous Androgen Use

Users whose axes have remained suppressed after months of standard recovery protocols are the hardest case. Some advanced approaches:

• Prolonged pulsatile KP-10 — 2-3 months of twice-daily 200-500 mcg rather than the 4-week beginner course. Hypothalamic recovery in chronically suppressed axes may require longer sustained stimulation.
• Sequential combinations — gonadorelin pulses for 4-6 weeks to restore pituitary responsiveness, followed by KP-10 to restore hypothalamic drive, followed by SERM tapering.
• Formal testing — GnRH stimulation test with measurement of LH response can distinguish hypothalamic from pituitary suppression and guide therapy choice.

Scenario 2: Functional Hypothalamic Hypogonadism (Exercise/Stress-Related)

In men or women with axis suppression from overtraining, chronic caloric restriction, or psychological stress, the underlying cause must be addressed alongside any peptide therapy. Kisspeptin can support the axis but will not overcome severe ongoing energy deficit or stress load. Advanced protocol:

• Normalize caloric intake and stress load first
• Add KP-10 100-250 mcg twice daily for 6-12 weeks
• Monitor axis recovery with labs and (in women) menstrual cycle resumption

Scenario 3: Age-Related Axis Decline (Late Onset Hypogonadism)

The evidence for kisspeptin in age-related hypogonadism is thinner than in functional or iatrogenic cases. The aging hypothalamus shows reduced kisspeptin neuron function, so exogenous kisspeptin may theoretically help, but most older men with low testosterone also have partial pituitary or gonadal component and respond well to TRT. Kisspeptin is not typically first-line for late-onset hypogonadism.

Scenario 4: Research-Grade Desire/HSDD Exploration

For experienced users interested in kisspeptin's central effects:

• Use carefully timed dosing before anticipated activity
• Combine with fMRI-validated approaches to understand individual response
• This is an active research frontier — expect improved protocols and selective kisspeptin analogs (MVT-602 and successors) to become available over the next several years

Engineered Kisspeptin Analogs: MVT-602 (Myovant Sciences) is a kisspeptin analog in clinical development with improved half-life (60-90 min vs ~4 min for KP-10). When available for research use, these analogs may enable once-daily or every-other-day dosing schedules with more sustained axis drive. For current practice, plain KP-10 remains the most accessible form.

Advanced Cautions:

• Kisspeptin is an upstream hormone with pleiotropic effects; long-term high-dose use without clinical supervision is not supported by evidence.
• Individual axis response varies substantially; reliance on lab-guided dosing is far more reliable than guessing from subjective symptoms.
• Any user with a hormone-sensitive cancer history should not use kisspeptin outside specific oncology-approved research contexts.